Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an
investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50%
or greater scalp hair loss. The study is placebo-controlled, meaning that some patients
entering the study will not receive active study drug but will receive tablets with no active
ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors,
the staff, and the patients will not know whether a patient is on active study drug (or the
dose) or placebo.